Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577003 | 1.00 | TSHR (0.56) | TSHRCYP3A4CASP6BACE1GPR35 | |
| Methane SCHEMBL27823028 | 0.98 | TSHR (0.54) | TSHRCYP3A4CASP6BACE1GPR35 | |
| Ethane SCHEMBL27988634 | 0.96 | TSHR (0.57) | TSHRCYP3A4CASP6BACE1GPR35 | |
| SCHEMBL29950169 | 0.84 | ESR1 (0.57) | TSHRBACE1GPR35EGFRESR1 | |
| SCHEMBL69947 | 0.84 | MAPK1 (0.67) | TSHRCYP3A4BACE1GPR35EGFR | |
| SCHEMBL29502912 | 0.84 | MAPK1 (0.67) | TSHRCYP3A4BACE1GPR35EGFR | |
| SCHEMBL6796101 | 0.84 | ESR1 (0.57) | TSHRBACE1GPR35EGFRESR1 | |
| SCHEMBL6031674 | 0.84 | MAPK1 (0.67) | TSHRCYP3A4BACE1GPR35EGFR | |
| SCHEMBL29479746 | 0.84 | GPR35 (0.67) | TSHRCYP3A4BACE1GPR35EGFR | |
| SCHEMBL68980 | 0.84 | GPR35 (0.67) | TSHRCYP3A4BACE1GPR35EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| CN-118010870-A | Method for simultaneously measuring multiple nitrophenol compounds in different food matrixes | 四川省食品检验研究院 | 2024-05-10 | — | — | CN | claimed |
| CN-116970180-A | Double-ligand energetic metal complex and preparation method thereof | 北京理工大学 | 2023-10-31 | — | — | CN | claimed |
| WO-2023205625-A2 | 2,4 DNP AND PRODRUGS THEREOF FOR TREATMENT OF PULMONARY AND AUTOIMMUNE DISEASES | MITOCHON PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| CN-116256943-A | Negative photosensitive resin composition, method for producing cured relief pattern, and semiconductor device | 旭化成株式会社 | 2023-06-13 | — | — | CN | claimed |
| US-20230100940-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | claimed |
| WO-2023014882-A1 | 2,4 DNP AND PRODRUGS THEREOF FOR TREATMENT OF CANCER | MITOCHON PHARMACEUTICALS, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| CN-115227685-A | DNP and DNP prodrug treatment of diseases | 米托充制药公司 | 2022-10-25 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| EP-3426233-A1 | DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES | Mitochon Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | claimed |
| US-20120296122-A1 | FLUOROETHER-FUNCTIONALIZED AMINOAROMATIC COMPOUNDS AND DERIVATIVES THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-22 | — | — | US | claimed |
| US-20120296123-A1 | FLUOROETHER-FUNCTIONALIZED NITROAROMATIC COMPOUNDS AND DERIVATIVES THEREOF | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-22 | — | — | US | claimed |
| WO-2012158302-A2 | FLUOROETHER-FUNCTIONALIZED NITROAROMATIC COMPOUNDS AND DERIVATIVES THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-22 | — | — | WO | claimed |
| US-6413679-B1 | HERMETIC SEALED CONTAINER | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-07-02 | — | — | US | claimed |
| EP-0411159-B1 | METHOD FOR DETERMINING ENZYMATIC ACTIVITY | IATRON LAB (JP) | 1995-11-22 | — | — | EP | claimed |
| US-5350677-A | Sampling and reaction, measuring color | IATRON LABORATORIES, INC. (JP) | 1994-09-27 | — | — | US | claimed |
| EP-0244799-B1 | AN ELECTROLYTE FOR ELECTROLYTIC CAPACITOR | NIPPON CHEMI-CON CORPORATION (JP) | 1991-03-06 | — | — | EP | claimed |
| EP-0411159-A1 | METHOD FOR DETERMINING ENZYMATIC ACTIVITY | IATRON LABORATORIES, INC. (JP) | 1991-02-06 | — | — | EP | claimed |
| US-4830785-A | ALKYL AMMONIUM OR AMINE SALTS OF PHENOL OR NITROPHENOL IN APROTIC SOLVENTS | NIPPON CHEMI-CON CORPORATION (JP) | 1989-05-16 | — | — | US | claimed |
| EP-0244799-A2 | An electrolyte for electrolytic capacitor | NIPPON CHEMI-CON CORPORATION (JP) | 1987-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296123-A1 | FLUOROETHER-FUNCTIONALIZED NITROAROMATIC COMPOUNDS AND DERIVATIVES THEREOF | PFAS, PARG, PARN | TSHR 4605/4885CYP3A4 54/4885CASP6 2785/4885 |
| US-20120296122-A1 | FLUOROETHER-FUNCTIONALIZED AMINOAROMATIC COMPOUNDS AND DERIVATIVES THEREOF | PARG, PARN, AADAC | TSHR 4682/4885CYP3A4 81/4885CASP6 2391/4885 |
| US-20230100940-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | TSHR 3498/4885CYP3A4 1498/4885CASP6 1382/4885 |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | DNPH1, SLC5A2, DNPEP | TSHR 2973/4885CYP3A4 149/4885CASP6 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.